Quick Answer
Neuphoria Therapeutics Inc. reported R&D Expense of $9.01 million for fiscal year 2025.
Neuphoria Therapeutics Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.01M | -4.4% |
| 2024 | $9.42M | -28.0% |
| 2023 | $13.07M | -18.3% |
| 2022 | $16.00M | +177.6% |
| 2021 | $5.76M | -1.1% |
| 2020 | $5.83M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $697.7K | -59.8% | -81.6% |
| September 30, 2025 | $3.79M | +99.2% | +134.3% |
| March 31, 2025 | $1.62M | +34.8% | -7.0% |
| December 31, 2024 | $1.74M | -14.6% | -8.6% |
| September 30, 2024 | $1.90M | -38.4% | +58.6% |
| March 31, 2024 | $1.20M | — | -41.1% |
| December 31, 2023 | $2.03M | — | -34.1% |
| September 30, 2023 | $3.09M | — | — |
- Neuphoria Therapeutics Inc. showed a decrease of -4.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Neuphoria Therapeutics Inc.’s r&d expense has grown by 54.5% (from $5.83 million to $9.01 million).
- The most recent figure is from Neuphoria Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: